Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week
HUTCHMED (China) is not owned by hedge funds. Hutchison Whampoa (China) Limited is currently the largest shareholder, with 39% of shares outstanding. In comparison, the second and third largest ...
pharmaphorum3d
Hutchmed cashes in a Chinese JV to help fund its pipeline
The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...
FiercePharma3d
With $608M divestment, Hutchmed continues to focus on ADC development
In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will ...
Yahoo Finance3d
HUTCHMED to divest 45% equity interest in SHPL for $608m
HUTCHMED (China) has agreed to sell a 45% equity interest in the non-core, non-consolidated joint venture (JV) Shanghai ...
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative ...
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including ...
BusinessMirror3d
Hutchmed sells stake in unit
Biopharmaceutical firm Hutchmed China Ltd., backed by Hong Kong billionaire Li Ka-shing, saw its shares rally on Thursday ...
Hutchmed announces progress, hits milestone with lung cancer treatment
Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment ...
The Asset3d
Hutchmed to sell stake in SHPL for 4.48 billion yuan
Limited, a biopharmaceutical company under Hong Kong-listed conglomerate CK Hutchison Holdings, has agreed to sell its 45% ...
GlobalData on MSN2d
China’s NMPA prioritises HUTCHMED’s lung cancer therapy review
China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...